A Multicenter, Randomized, Open-label Phase II Clinical Study on the Efficacy and Safety of HRS-1893 in Obstructive Hypertrophic Cardiomyopathy Subjects.

NCT06516068 Phase 2 ACTIVE_NOT_RECRUITING

The study is being conducted to evaluate the efficacy, and safety of HRS-1893 for obstructive hypertrophic cardiomyopathy

Details

Lead sponsor	Shandong Suncadia Medicine Co., Ltd.
Phase	Phase 2
Status	ACTIVE_NOT_RECRUITING
Enrolment	42
Start date	2024-08-11
Completion	2025-08

Conditions

• Obstructive Hypertrophic Cardiomyopathy

Interventions

• HRS-1893

Primary outcomes

• The subjects' left ventricular outflow tract pressure gradient (Valsalva LVOT-G) was assessed for changes from the baseline after performing the Valsalva maneuver — After 12 weeks of HRS-1893 treatment

Countries

China